ImmunityBio Business Summary

ImmunityBio, Inc. (IBRX) is a vertically integrated, commercial-stage biotechnology company that generates revenue primarily through the global sale of its lead therapeutic, ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor superagonist. The company operates across three primary business segments: oncology, infectious diseases, and large-scale biologics manufacturing, maintaining over one million square feet of production capacity to control its entire product lifecycle. As of February 2026, ImmunityBio has achieved significant commercial scale, reporting a 700% year-over-year revenue increase to $113 million in FY2025, driven by the rapid adoption of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and its recent expansion into metastatic non-small cell lung cancer (NSCLC) in international markets like Saudi Arabia and the EU. Within the competitive landscape, ImmunityBio competes directly with immunotherapy and oncology leaders such as BioNTech (BNTX), Roivant Sciences (ROIV), and Genmab A/S (GMAB). It distinguishes itself as a market leader in "Immunotherapy 2.0," leveraging its proprietary cytokine fusion protein and natural killer (NK) cell platforms to address critical supply gaps in standard-of-care treatments like BCG. The company was founded by Dr. Patrick Soon-Shiong, a billionaire surgeon and scientist who serves as Executive Chairman and Global Chief Scientific and Medical Officer. The executive leadership team is led by CEO and President Richard Adcock, a Six Sigma Master Black Belt formerly of Verity Health and Sanford Health, who is credited with the company's successful commercial pivot. Other key officers include CFO David C. Sachs, who oversees the firm's complex capital structure, and CTO Dr. Enrique Diloné, who manages the technical operations of its expansive manufacturing footprint. The Board of Directors features high-profile figures including General (Retd.) Wesley Clark and recently appointed independent director Bruce Wendel, the former CEO of Abraxis BioScience. ImmunityBio is backed by significant institutional and private investment, with major stakes held by California Capital Equity, LLC (Soon-Shiong’s investment vehicle), NantWorks, LLC, and institutional giants such as The Vanguard Group and BlackRock.